Scienture Holdings, Inc. 成功获得一项美国专利，该专利覆盖了其产品 Rezenopy™（盐酸纳洛酮）鼻喷雾剂 10 毫克的特定范围。此项专利的授予，显著强化了公司对该关键产品的知识产权保护，其保护期限将一直持续到 2041 年。
这项专利不仅巩固了 Scienture 在其核心治疗领域的技术壁垒，也为 Rezenopy™ 这一重要药品的商业前景提供了长期、稳固的法律保障。通过将专利保护期延长至 2041 年，公司有效维护了其市场独占地位，为未来的持续发展和市场拓展奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.